title: Radiographic and metabolic response rates following image-guided stereotactic radiotherapy for lung tumors.
abstract: OBJECTIVE
  To evaluate radiographic and metabolic response after stereotactic body radiotherapy (SBRT) for early lung tumors.
  
  
  METHODS
  Thirty-nine tumors were treated prospectively with SBRT (dose=48-60 Gy, 4-5 Fx). Thirty-six cases were primary NSCLC (T1N0=67%; T2N0=25%); three cases were solitary metastases. Patients were followed using CT and PET at 6, 16, and 52 weeks post-SBRT, with CT follow-up thereafter. RECIST and EORTC criteria were used to evaluate CT and PET responses.
  
  
  RESULTS
  At median follow-up of 9 months (0.4-26), RECIST complete response (CR), partial response (PR), and stable disease (SD) rates were 3%, 43%, 54% at 6 weeks; 15%, 38%, 46% at 16 weeks; 27%, 64%, 9% at 52 weeks. Mean baseline tumor volume was reduced by 46%, 70%, 87%, and 96%, respectively at 6, 16, 52, and 72 weeks. Mean baseline maximum standardized uptake value (SUV) was 8.3 (1.1-20.3) and reduced to 3.4, 3.0, and 3.7 at 6, 16, and 52 weeks after SBRT. EORTC metabolic CR/PR, SD, and progressive disease rates were 67%, 22%, 11% at 6 weeks; 86%, 10%, 3% at 16 weeks; 95%, 5%, 0% at 52 weeks.
  
  
  CONCLUSIONS
  SBRT yields excellent RECIST and EORTC based response. Metabolic response is rapid however radiographic response occurs even after 1-year post treatment.
authors: Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI 48073, USA.
authors: Nasiruddin
authors: N
authors: Mohammed
authors: Inga S
authors: IS
authors: Grills
authors: Ching-Yee Oliver
authors: CY
authors: Wong
authors: Ana Paula
authors: AP
authors: Galerani
authors: Kenneth
authors: K
authors: Chao
authors: Robert
authors: R
authors: Welsh
authors: Gary
authors: G
authors: Chmielewski
authors: Di
authors: D
authors: Yan
authors: Larry L
authors: LL
authors: Kestin
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015897:Comorbidity; D003287:Contrast Media / Q000493:pharmacokinetics; D018450:Disease Progression; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011446:Prospective Studies; D015641:Radiography, Interventional; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D016634:Radiosurgery / Q000379:methods*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D003287:Contrast Media; D019275:Radiopharmaceuticals